Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017059 | 1.00 | LMNA (0.48) | LMNASIRT6HTTPOLBCYP3A4 | |
| SCHEMBL1614754 | 0.91 | MAPT (0.49) | LMNAHTTPOLBABCB1ABCG2 | |
| SCHEMBL4430393 | 0.90 | KDM4E (0.46) | LMNAHTTPOLBCYP3A4NPC1 | |
| SCHEMBL22974948 | 0.89 | SIRT6 (0.48) | LMNASIRT6POLBKDM4EMEN1 | |
| SCHEMBL26651133 | 0.88 | MAPT (0.51) | LMNAHTTPOLBCYP3A4NPC1 | |
| SCHEMBL8305629 | 0.83 | POLB (0.42) | LMNAHTTPOLBABCG2MEN1 | |
| SCHEMBL8305831 | 0.82 | EHMT2 (0.44) | SIRT6MAPTKDRALDH1A1L3MBTL1 | |
| SCHEMBL21473565 | 0.82 | KDM4E (0.58) | LMNACYP3A4KDM4EKDRALDH1A1 | |
| SCHEMBL30017160 | 0.82 | KDM4E (0.58) | LMNACYP3A4KDM4EKDRALDH1A1 | |
| SCHEMBL17375521 | 0.81 | SIRT6 (0.51) | LMNASIRT6HTTPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112236422-B | Quinazoline compound as EGFR three-mutation inhibitor and application thereof | 华东理工大学 | 2023-05-16 | — | — | CN | disclosed |
| CN-115403557-A | Quinoline and quinazoline compounds as fourth-generation EGFR (epidermal growth factor receptor) inhibitor and application thereof | 华东理工大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-110372666-B | Quinazoline compound as EGFR (epidermal growth factor receptor) triple mutation inhibitor and application thereof | 华东理工大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3778586-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | East China University of Science and Technology (CN) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778586-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | East China University of Science and Technology (CN) | 2021-02-17 | — | — | EP | disclosed |
| CN-112236422-A | Quinazoline compound as EGFR (epidermal growth factor receptor) triple mutation inhibitor and application thereof | 华东理工大学 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019196938-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EGFR, ERBB2, ERBB4 | LMNA 4591/4885SIRT6 2907/4885HTT 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.